115 related articles for article (PubMed ID: 21040805)
1. Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Busk M; Bohn AB; Skals M; Wang T; Horsman MR
Vascul Pharmacol; 2011; 54(1-2):13-7. PubMed ID: 21040805
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Ley CD; Kristjansen PE; Horsman MR
Acta Oncol; 2010 Oct; 49(7):906-13. PubMed ID: 20831477
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
6. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.
Zhao D; Chang CH; Kim JG; Liu H; Mason RP
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):574-81. PubMed ID: 21345614
[TBL] [Abstract][Full Text] [Related]
7. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
8. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
Hokland SL; Horsman MR
Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
10. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
12. Vascular targeting: a potential additional anti-cancer treatment.
Lambin P; Landuyt W
Verh K Acad Geneeskd Belg; 2003; 65(1):29-46. PubMed ID: 12802895
[TBL] [Abstract][Full Text] [Related]
13. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anti-vascular therapy with texture analysis.
Chen G; Jespersen S; Pedersen M; Pang Q; Horsman MR; Stødkilde Jørgensen H
Anticancer Res; 2005; 25(5):3399-405. PubMed ID: 16101155
[TBL] [Abstract][Full Text] [Related]
15. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
16. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.
Griggs J; Skepper JN; Smith GA; Brindle KM; Metcalfe JC; Hesketh R
Am J Pathol; 2002 Mar; 160(3):1097-103. PubMed ID: 11891206
[TBL] [Abstract][Full Text] [Related]
18. Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.
Li J; Dong X; Xu Z; Jiang X; Jiang H; Krissansen GW; Sun X
J Biomed Sci; 2008 Jan; 15(1):99-109. PubMed ID: 17705027
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Salmon BA; Siemann DW
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):211-7. PubMed ID: 17448875
[TBL] [Abstract][Full Text] [Related]
20. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
